Discriminant Efficacy of mpMRI for Variant Pathology Associated with Prostate Adenocarcinoma

dc.authoridKöseoğlu, Hikmet/0000-0001-5678-4981
dc.authorwosidKöseoğlu, Hikmet/A-8081-2008
dc.contributor.authorKoseoglu, Hikmet
dc.contributor.authorCenkeri, Halime Cevik
dc.contributor.authorEroglu, Tolga
dc.contributor.authorYalcin, Berrin
dc.date.accessioned2024-05-25T11:37:58Z
dc.date.available2024-05-25T11:37:58Z
dc.date.issued2023
dc.departmentOkan Universityen_US
dc.department-temp[Koseoglu, Hikmet] Hlth Sci Univ, Hamidiye Fac Med, Istanbul Hlth Practice & Res Ctr, Dept Urol, Istanbul, Turkiye; [Cenkeri, Halime Cevik] Okan Univ, Fac Med, Dept Radiol, Istanbul, Turkiye; [Eroglu, Tolga] Semdinli State Hosp, Dept Urol, Hakkari, Turkiye; [Yalcin, Berrin] Hlth Sci Univ, Hamidiye Fac Med, Istanbul Hlth Practice & Res Ctr, Dept Radiat Oncol, Istanbul, Turkiyeen_US
dc.descriptionKöseoğlu, Hikmet/0000-0001-5678-4981en_US
dc.description.abstractPurpose: Implementation of multiparametric magnetic resonance imaging (mpMRI) for prostate adenocarcino-ma's variant pathology requires awareness. The aim of this retrospective study was to investigate the discriminant efficacy of multiparametric magnetic resonance imaging modality for variant pathology associated with prostate adenocarcinoma. Methods: Consecutive 247 prostate cancer patients who underwent radical prostatectomy in our university-based hospital between October 2014 and October 2019, were retrospectively reviewed. Data of mpMRI-associated contrast enhancements, T2 signals, apparent diffusion coefficients (ADC), ages, and PSA values were compared. Clinical and demographic data of patients were noted including associated variant pathologies and reports of pre-operative mpMRI images. Results: Among the patients, 63 (26%) had variant pathology and 14 (22%) had mpMRI before primary prostate biopsy. The group with variant pathology and the control group had similar perfusion curves and increased contrast when compared for mpMRI parameters, but different ADC values for each of the adjusted b-values for 400, 800 and 1400. Conclusion: Our study demonstrates that mpMRI appears to have no role in distinguishing rare variant pathologies associated with prostate adenocarcinoma despite different ADC values.en_US
dc.description.sponsorship[10-11 Oc- tober 2020]en_US
dc.description.sponsorshipACKNOWLEDGEMENT It was presented as poster in the 40th Congress of the Societe Internationale d'Urologie- Virtual, 10-11 Oc- tober 2020.en_US
dc.identifier.citation0
dc.identifier.doi10.22037/uj.v20i.7468]
dc.identifier.endpage161en_US
dc.identifier.issn1735-1308
dc.identifier.issn1735-546X
dc.identifier.issue3en_US
dc.identifier.pmid36840448
dc.identifier.startpage157en_US
dc.identifier.urihttps://doi.org/10.22037/uj.v20i.7468]
dc.identifier.urihttps://hdl.handle.net/20.500.14517/1235
dc.identifier.volume20en_US
dc.identifier.wosWOS:000996100500004
dc.language.isoen
dc.publisherUrol & Nephrol Res Ctr-unrcen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectprostate adenocarcinomaen_US
dc.subjectprostate cancer variantsen_US
dc.subjectmpMRIen_US
dc.subjectapparent diffusion coefficienten_US
dc.titleDiscriminant Efficacy of mpMRI for Variant Pathology Associated with Prostate Adenocarcinomaen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files